These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 10748157

  • 1. Interaction of the tumor suppressor PTEN/MMAC with a PDZ domain of MAGI3, a novel membrane-associated guanylate kinase.
    Wu Y, Dowbenko D, Spencer S, Laura R, Lee J, Gu Q, Lasky LA.
    J Biol Chem; 2000 Jul 14; 275(28):21477-85. PubMed ID: 10748157
    [Abstract] [Full Text] [Related]

  • 2. Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2.
    Wu X, Hepner K, Castelino-Prabhu S, Do D, Kaye MB, Yuan XJ, Wood J, Ross C, Sawyers CL, Whang YE.
    Proc Natl Acad Sci U S A; 2000 Apr 11; 97(8):4233-8. PubMed ID: 10760291
    [Abstract] [Full Text] [Related]

  • 3. Binding of PTEN to specific PDZ domains contributes to PTEN protein stability and phosphorylation by microtubule-associated serine/threonine kinases.
    Valiente M, Andrés-Pons A, Gomar B, Torres J, Gil A, Tapparel C, Antonarakis SE, Pulido R.
    J Biol Chem; 2005 Aug 12; 280(32):28936-43. PubMed ID: 15951562
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex.
    Vazquez F, Grossman SR, Takahashi Y, Rokas MV, Nakamura N, Sellers WR.
    J Biol Chem; 2001 Dec 28; 276(52):48627-30. PubMed ID: 11707428
    [Abstract] [Full Text] [Related]

  • 9. In vivo gene therapy of human bladder cancer with PTEN suppresses tumor growth, downregulates phosphorylated Akt, and increases sensitivity to doxorubicin.
    Tanaka M, Grossman HB.
    Gene Ther; 2003 Sep 28; 10(19):1636-42. PubMed ID: 12923562
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN.
    Davies MA, Koul D, Dhesi H, Berman R, McDonnell TJ, McConkey D, Yung WK, Steck PA.
    Cancer Res; 1999 Jun 01; 59(11):2551-6. PubMed ID: 10363971
    [Abstract] [Full Text] [Related]

  • 13. Tumor suppressor MMAC/PTEN inhibits cytokine-induced NFkappaB activation without interfering with the IkappaB degradation pathway.
    Koul D, Yao Y, Abbruzzese JL, Yung WK, Reddy SA.
    J Biol Chem; 2001 Apr 06; 276(14):11402-8. PubMed ID: 11278366
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.
    Georgescu MM, Kirsch KH, Akagi T, Shishido T, Hanafusa H.
    Proc Natl Acad Sci U S A; 1999 Aug 31; 96(18):10182-7. PubMed ID: 10468583
    [Abstract] [Full Text] [Related]

  • 20. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association.
    Lee JO, Yang H, Georgescu MM, Di Cristofano A, Maehama T, Shi Y, Dixon JE, Pandolfi P, Pavletich NP.
    Cell; 1999 Oct 29; 99(3):323-34. PubMed ID: 10555148
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.